PFS
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xinyi He, Mengting Shi, Lin Zhang, Jianhua Zhan, Jiaqing Liu, Dongchen Sun, Zihong Chen, Shaodong Hong, Yaxiong Zhang, Gang Chen, Shen Zhao, Ting Zhou, Wenfeng Fang, Yuanyuan Zhao, Yan Huang, Caicun Zhou, Yunpeng Yang, Li Zhang, Huaqiang Zhou
BMC Cancer 25(1) 1380
BACKGROUND: Baseline tumor burden (TB), measured radiographically, has emerged as a potential biomarker for stratifying survival outcomes with immune checkpoint inhibitors (ICI) across solid tumors. However, the predictive value for ICI plus chemotherapy (chemoimmunotherapy) in NSCLC has not been confirmed with large cohorts that include a chemotherapy-only control group. METHODS: This post hoc analysis utilized data from ORIENT-11 trial, a phase III, randomized clinical trial of advanced NSCLC patients who were administered with either chemoimmunotherapy or chemotherapy alone. TB was measured as the sum of the diameters of target lesions at baseline following RECIST 1.1 criteria. The relationships between baseline TB and outcomes were assessed using the Cox proportional hazards model. Validation was conducted using data from ORIENT-12 trial. RESULTS: In chemoimmunotherapy arm, patients with low TB demonstrated longer progression-free survival (PFS: 11.60 vs. 7.20 months, hazard ratio [HR] = 0.625, p = 0.004) and overall survival (OS: 28.77 vs. 20.10 months, HR = 0.683, p = 0.020) compared to those with high TB. In the chemotherapy-only arm, no significant survival differences were observed based on TB levels. Multivariate analyses confirmed that regardless of tumoral PD-L1 expression, low TB as an independent marker of improved survival with chemoimmunotherapy. Patients with high TB and low PD-L1 expression had the shortest survival, deriving minimal benefit from chemoimmunotherapy over chemotherapy alone (PFS: 5.53 vs. 5.07 months; OS: 10.52 vs. 13.80 months). These findings were validated in ORIENT-12 cohort. CONCLUSIONS: Baseline TB is a predictive, rather than prognostic, clinical biomarker for survival outcomes in advanced NSCLC patients treated with chemoimmunotherapy. TB assessment, integrated with PD-L1 status evaluation, may improve patient stratification for first-line chemoimmunotherapy in clinical practice and provide valuable insight for the clinical trials designs.
2 个 Figure · 10 个 KM 面板
Fig. 1 Survival outcomes of NSCLC patients treated with chemoimmunotherapy or chemotherapy. A , B Kaplan–Meier PFS ( A ) and OS ( B ) curves of NSCLC patients treated with chemoimmunotherapy (combo) stratified by TB. C, D Kaplan–Meier PFS ( C ) and OS ( D ) curves of NSCLC patients treated with chemotherapy (chemo) stratified by TB. E, F Kaplan–Meier PFS ( E ) and OS ( F ) curves of patients stratified by assigned treatment and TB, and the results of subgroup analyses. Abbreviation: Chemo, chemotherapy; CI, confidence interval; Combo, chemoimmunotherapy; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; TB, tumor burden
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel D
Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel E
Panel E 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel F
Panel F 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 Survival outcomes of patients stratified by TB and PD-L1 expression. A, B Kaplan–Meier PFS ( A ) and OS ( B ) curves of NSCLC patients treated with chemoimmunotherapy stratified by TB and PD-L1 TPS (≥ 1%/< 1%). C, D Kaplan–Meier PFS ( C ) and OS ( D ) curves of NSCLC patients treated with chemotherapy stratified by TB and PD-L1 TPS (≥ 1%/< 1%). Abbreviation: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PD-L1, programmed death-ligand 1; TB, tumor burden; TPS, tumor proportional score
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D
Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。